KR20120068889A - 뮤신 분비를 억제하기 위한 구아이페네신의 용도 - Google Patents
뮤신 분비를 억제하기 위한 구아이페네신의 용도 Download PDFInfo
- Publication number
- KR20120068889A KR20120068889A KR1020127007996A KR20127007996A KR20120068889A KR 20120068889 A KR20120068889 A KR 20120068889A KR 1020127007996 A KR1020127007996 A KR 1020127007996A KR 20127007996 A KR20127007996 A KR 20127007996A KR 20120068889 A KR20120068889 A KR 20120068889A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- administering
- effective amount
- guapefensin
- guipenesin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000028327 secretion Effects 0.000 title claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- 108010063954 Mucins Proteins 0.000 title claims description 29
- 102000015728 Mucins Human genes 0.000 title claims description 29
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 title description 2
- 229960002146 guaifenesin Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 210000003097 mucus Anatomy 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims description 11
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 230000000954 anitussive effect Effects 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 229940124584 antitussives Drugs 0.000 claims description 5
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims description 3
- ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 claims description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical group OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 3
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims description 3
- 229960005008 doxylamine succinate Drugs 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
- 229960003592 fexofenadine Drugs 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 3
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 3
- 229960002254 phenyltoloxamine citrate Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims 4
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000003434 antitussive agent Substances 0.000 claims 2
- 229960002881 clemastine Drugs 0.000 claims 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 2
- 229940124581 decongestants Drugs 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 229960003108 brompheniramine maleate Drugs 0.000 claims 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000518 rheometry Methods 0.000 description 7
- 210000004081 cilia Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 102100022496 Mucin-5AC Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000420 mucociliary effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/558,517 US20110065744A1 (en) | 2009-09-12 | 2009-09-12 | Method Of Inhibiting Mucin Secretion |
| US12/558,517 | 2009-09-12 | ||
| GBGB1002039.4A GB201002039D0 (en) | 2010-02-09 | 2010-02-09 | Method of inhibiting mucin secretion |
| GB1002039.4 | 2010-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120068889A true KR20120068889A (ko) | 2012-06-27 |
Family
ID=42941393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127007996A Withdrawn KR20120068889A (ko) | 2009-09-12 | 2010-09-13 | 뮤신 분비를 억제하기 위한 구아이페네신의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2475360A1 (https=) |
| JP (1) | JP2013504554A (https=) |
| KR (1) | KR20120068889A (https=) |
| CN (1) | CN102596189A (https=) |
| AU (1) | AU2010294008B2 (https=) |
| BR (1) | BR112012005517A2 (https=) |
| CA (1) | CA2773611A1 (https=) |
| MX (1) | MX2012003042A (https=) |
| MY (1) | MY161187A (https=) |
| RU (1) | RU2012114323A (https=) |
| WO (1) | WO2011030163A1 (https=) |
| ZA (1) | ZA201201822B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190102465A (ko) * | 2018-02-26 | 2019-09-04 | 대한민국(환경부 국립생물자원관장) | 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150065539A1 (en) * | 2012-04-06 | 2015-03-05 | The Uab Research Foundation | Methods for Increasing CFTR Activity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA963590B (en) * | 1995-05-10 | 1996-11-19 | Adcock Ingram Ltd | Pharmaceutical composition |
| US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| US20040029864A1 (en) * | 2002-02-04 | 2004-02-12 | Pharmacia Corporation | Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof |
| EP1633734A2 (en) * | 2003-06-19 | 2006-03-15 | Genaera Corporation | Mucin synthesis inhibitors |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| US20080014261A1 (en) * | 2006-07-12 | 2008-01-17 | Giordano John A | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
| US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
-
2010
- 2010-09-13 WO PCT/GB2010/051525 patent/WO2011030163A1/en not_active Ceased
- 2010-09-13 BR BR112012005517A patent/BR112012005517A2/pt not_active Application Discontinuation
- 2010-09-13 MX MX2012003042A patent/MX2012003042A/es unknown
- 2010-09-13 EP EP10757117A patent/EP2475360A1/en not_active Ceased
- 2010-09-13 MY MYPI2012001112A patent/MY161187A/en unknown
- 2010-09-13 JP JP2012528455A patent/JP2013504554A/ja active Pending
- 2010-09-13 CA CA2773611A patent/CA2773611A1/en not_active Abandoned
- 2010-09-13 KR KR1020127007996A patent/KR20120068889A/ko not_active Withdrawn
- 2010-09-13 RU RU2012114323/15A patent/RU2012114323A/ru unknown
- 2010-09-13 CN CN2010800492171A patent/CN102596189A/zh active Pending
- 2010-09-13 AU AU2010294008A patent/AU2010294008B2/en not_active Ceased
-
2012
- 2012-03-13 ZA ZA2012/01822A patent/ZA201201822B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190102465A (ko) * | 2018-02-26 | 2019-09-04 | 대한민국(환경부 국립생물자원관장) | 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| MY161187A (en) | 2017-04-14 |
| EP2475360A1 (en) | 2012-07-18 |
| CA2773611A1 (en) | 2011-03-17 |
| AU2010294008A1 (en) | 2012-04-05 |
| BR112012005517A2 (pt) | 2016-04-19 |
| CN102596189A (zh) | 2012-07-18 |
| WO2011030163A1 (en) | 2011-03-17 |
| JP2013504554A (ja) | 2013-02-07 |
| ZA201201822B (en) | 2013-05-29 |
| AU2010294008B2 (en) | 2014-08-14 |
| MX2012003042A (es) | 2012-05-29 |
| RU2012114323A (ru) | 2013-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zanasi et al. | A reappraisal of the mucoactive activity and clinical efficacy of bromhexine | |
| Caldwell et al. | Mitochondrial abnormalities in non-alcoholic steatohepatitis | |
| Hu et al. | Dental pulp stem cell-derived exosomes revitalize salivary gland epithelial cell function in NOD mice via the GPER-mediated cAMP/PKA/CREB signaling pathway | |
| Seagrave et al. | Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells | |
| Rogers | Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options | |
| Sagar et al. | Obesity impairs cardiolipin-dependent mitophagy and therapeutic intercellular mitochondrial transfer ability of mesenchymal stem cells | |
| Richter et al. | Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease | |
| Zhang et al. | 18β-Glycyrrhetinic acid monoglucuronide (GAMG) alleviates single-walled carbon nanotubes (SWCNT)-induced lung inflammation and fibrosis in mice through PI3K/AKT/NF-κB signaling pathway | |
| Wen et al. | Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways | |
| Dekker et al. | Stress‐induced responses of human skin fibroblasts in vitro reflect human longevity | |
| Lo Bello et al. | Role of the mucins in pathogenesis of COPD: implications for therapy | |
| Martin et al. | Palate lung nasal clone (PLUNC), a novel protein of the tear film: three-dimensional structure, immune activation, and involvement in dry eye disease (DED) | |
| Su et al. | Mitochondrial transplantation attenuates airway hyperresponsiveness by inhibition of cholinergic hyperactivity | |
| KR20120068889A (ko) | 뮤신 분비를 억제하기 위한 구아이페네신의 용도 | |
| Xiang et al. | Unexpected inhibitory role of silica nanoparticles on lung cancer development by promoting M1 polarization of macrophages | |
| Jiang et al. | Glycyrrhetinic acid ameliorates gastric mucosal injury by modulating gut microbiota and its metabolites via Thbs1/PI3K-Akt/p53 pathway | |
| Peng et al. | Adverse impact of ambient PM2. 5 on expression and trafficking of surfactant protein A through reactive oxygen species damage to lamellar bodies | |
| Miyata et al. | Current opinion of muco-active drug research: strategies and problems | |
| Barac et al. | Chronic rhinosinusitis: association of recalcitrant nasal polyposis and fungal finding in polyp’s single-cell suspension | |
| Wang et al. | From perinodular to nodular tissues: aberrant accumulation of ornithine accelerates pulmonary fibrosis in silicosis | |
| Jie et al. | Sclareol alleviates synovial inflammation in knee osteoarthritis by regulating sphingolipid metabolism along the gut–bone axis | |
| US20110065744A1 (en) | Method Of Inhibiting Mucin Secretion | |
| Wang et al. | Combined use of hydrogen-rich water and enzyme-digested edible bird’s nest improves PMA/LPS-impaired wound healing in human inflammatory gingival tissue equivalents | |
| Bojan et al. | A study to determine the association between tobacco smoking habit and oral candidal infection in median rhomboid glossitis by cytologic and histopathologic methods | |
| KR102617037B1 (ko) | 폐암 재발 예측방법 및 재발 억제용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120328 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |